Bradford et al. investigated the anti-tumor activity of the pan-class I PI3K inhibitor NVP BKM-120 (BKM) as a single agent and in combination with standard cytotoxic chemotherapy (PTX-CBP) in NOD/SCID mice bearing subcutaneous xenografts of either a PIK3CA mutant or PIK3CA wild-type endometrial tumors (grade 2 or 3 and of endometrioid, serous (USC) and carcinosarcoma histological subtypes). The gene discussed is PIK3CA; the disease is carcinosarcoma.